This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
milla1cf Tue, 01/09/2024 - 11:32 January 9, 2024 — Cleerly , the company working to create a new standard of care for the diagnosis of heart disease, announced the launch of Cleerly ISCHEMIA , which recently received U.S. Cleerly ISCHEMIA is a transformative addition poised to reshape the landscape of cardiac care.”
milla1cf Thu, 05/16/2024 - 15:35 May 16, 2024 — A recent publication in the American Heart Association Circulation highlights a comprehensive investigation to assess the impact of revascularization strategies on the health-related quality of life (HRQoL) of patients suffering from chronic limb-threatening ischemia.
The Freesolve BTK RMS is designed for individuals suffering from chronic limb-threatening ischemia (CLTI). Biotronik 's focus on vascular interventional excellence is evident in our strategic investments and persistent dedication to innovation”, said Dr. Jörg Pochert, President of Vascular Intervention at Biotronik.
Food and Drug Administration (FDA) for its DynamX BTK System, a novel, adaptive implant for use in the treatment of narrowed or blocked vessels below-the-knee (BTK) in patients with chronic limb-threatening ischemia (CLTI). The natural history of untreated severe or critical limb ischemia. 2013;382(9901):1329-1340. J Vasc Surg.
This AI technology can detect 35 cardiac determinations (14 arrhythmias and 21 morphologies), including serious conditions like acute myocardial infarction ( MI ) and the most common types of cardiac ischemia, using a reduced leadset.
The benefits of QFR guidance are supported in a recent study that showed that a QFR-guided strategy of lesion selection for PCI improved two-year clinical outcomes, including reduction in myocardial infraction and ischemia-driven revascularization, when compared with standard angiography guidance alone.2
6 This novel study marks a significant milestone in the field, evaluating the effectiveness of FFR CT in detecting ischemia-producing coronary stenosis in patients with severe PAD. Diagnosis and treatment of ischemia-producing coronary stenoses improves 5-year survival of patients undergoing major vascular surgery.” 2024, [link].
The CAD Staging System is a noninvasive imaging-based investigational software device that analyzes important and actionable features of coronary atherosclerosis, stenosis and ischemia. Cleerly’s mission extends beyond innovation; it is a commitment to saving lives by revolutionizing the prevention and treatment of heart disease.
Previous to GWU, Earls served as Medical Director and Vice President at Fairfax Radiological Consultants (FRC) in Fairfax, VA, where he was an early innovator and clinical adopter of coronary CT angiography. High Diagnostic Accuracy Of AI-Ischemia in Comparison To PET, FFR-CT, SPECT, and Invasive FFR: A PACIFIC Sub-Study.
a leader in the development of innovative biologics to treat acute and chronic cardiovascular disease , presented data from a recent large animal study performed by VST Bio and Yale University demonstrating that a single iv bolus of VST-002 led to meaningful reduction in brain damage and improved function in an advanced model of ischemic stroke.
The major processes involved in such decline include early brain injury, delayed cerebral ischemia, neuroinflammation, superficial siderosis, and hydrocephalus. These have emerging treatments that offer promise for the mitigation of effects such as inflammation, iron chelation, and microvascular dysfunction.
of enrolled patients had critical limb ischemia, 90% had calcified lesions (30.7% The features of this device illustrate our commitment to innovation, and now we have evidence to support the utility of this design.” At baseline, 12.5% severe calcification), and there was an average of 85.5% stenosis in the target lesion.
Shishehbor, President of UH Harrington Heart & Vascular Institute, and Angela and James Hambrick Chair in Innovation at UH. Through this center, Lorraine and Bill are helping to expand access to lifesaving vascular resources and enhance opportunities for medical innovation and discovery, said Cliff A.
Shishehbor, President of UH Harrington Heart & Vascular Institute, and Angela and James Hambrick Chair in Innovation at UH. Through this center, Lorraine and Bill are helping to expand access to lifesaving vascular resources and enhance opportunities for medical innovation and discovery, said Cliff A.
BackgroundThe rapid evolution of artificial intelligence (AI) in conjunction with recent updates in dual antiplatelet therapy (DAPT) management guidelines emphasizes the necessity for innovative models to predict ischemic or bleeding events after drug‐eluting stent implantation.
Helpful in defining the extent of ischemia, prognosis, and neurological severity, the role of each item in the score is not clear in the literature. Our results bring to the literature an innovative tool for numerically assessing the clinical-radiological mismatch using a simple and accessible neuroimaging method.
So, we desperately required to break this inappropriate menace with evidence base like COURAGE, ISCHEMIA, BARI-2D, These studies tried to apply some breaks, but the force was weak and couldn’t abolish a pseudo-academic vice. In the process, the abuse prevailed over the use, causing considerable damage.
Traditional methods of non-invasive ischemia testing (stress EKG , stress echo, SPECT , PET , direct-to-cath) can result in false negatives 20-30 percent of the time, which can lead to undetected disease, and false positives over 50 percent of the time, which can lead to unnecessary invasive procedures.
ET Main Tent (Hall B1) This session offers more insights from key clinical trials presented at ACC.24 24 and find out what it all means for your patients.
Still, Mirowski”s electrical kid survived the test of time and evolved with great technological innovations from companies like Medtronic, Guidant, Abbot etc. The simple reason could be we can address the ischemia a potential arrhythmic target by some form of revascularization in IDCM.
We hope that the anniversary contributions will help to support the college's mission and mission-focused work that empowers future leaders in the next generation of cardiovascular innovators through scholarship, mentorship and leadership development programs. “We Session 510) To Treat or Not to Treat Anatomy and Ischemia?
Cardiologs founder, Yann Flereau, was named by MIT as the European Innovator of the Year. A Deep Neural Network learning algorithm outperforms a conventional algorithm for emergency department electrocardiogram interpretation. What an honor. This ECG is displayed on the Cardiologs platform. What do you think?
September 2024 Approvals Flurpiridaz F 18 Approval Date: September 27, 2024 Indication: A radioactive positron emission tomography (PET) tracer for imaging myocardial ischemia and infarction in adults with suspected or known coronary artery disease.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content